Showing posts with label global fund. Show all posts
Showing posts with label global fund. Show all posts

Wednesday, 25 January 2012

Head of Global Fund resigns!

Resignation letter original link here  Also Laurie Garrett's  response below


A MESSAGE TO STAFF, PARTNERS AND FRIENDS FROM THE EXECUTIVE DIRECTOR

Date : 24 January 2012
Dear Friends and Colleagues,
This has been a difficult letter to write.  Its purpose is to inform you of my decision to step down from my position as Executive Director of the Global Fund by March 16, 2012.
For the last ten years, the Global Fund has been my passion and my most important undertaking.  As a member of the Transitional Working Group in 2001 that laid down the basic structure and principles of the Fund, as the first Chair of the Technical Review Panel from 2002 to 2005, as the Vice-Chair of the Board in 2005 and 2006, and in my five years as Executive Director, I have been deeply committed to helping the Global Fund achieve its vision of a world free of AIDS, tuberculosis and malaria.
No institution is perfect, and the Global Fund is no exception.  Yet, I am immensely proud of what the Global Fund has achieved in these ten years, and I am tremendously grateful that I have been able to play a central part in its evolution and success.  As a physician, I am particularly proud of the role that the Fund has played in reducing human suffering and saving lives.  Through its strong focus on human rights, the Global Fund is also helping to protect vulnerable groups in many countries who suffer discrimination, persecution and indignity.  And with its principle of country ownership and its unique power-sharing and multi-stakeholder governance structure of governments, civil society and the private sector, the Global Fund has helped to spearhead an entirely new framework of international development partnership.   Although we still have a long way to go to make this new approach work in every country, I believe that the Global Fund has permanently changed the development landscape for the better. 
In this year of the Fund’s tenth anniversary, there is much to celebrate.  The Global Fund has been a force for good and has helped to make the world a better place. 
Today, the Global Fund stands at a cross-road.  The High-Level Panel which delivered its report last September clearly stated that the Fund must adapt to the different realities of its second decade.  The prevailing economic climate poses new and formidable challenges to all international development efforts.  In the international political economy, power-balances are shifting and new alignments of countries and decision-making institutions are emerging or will have to be developed to achieve global goals.  Within the area of global health, the emergency approaches of the past decade are giving way to concerns about how to ensure long-term sustainability, while at the same time, efficiency is becoming a dominant measure of success.
My belief that the Global Fund has an indispensable role to play in the coming decade is unwavering and I am confident that the rationale, targets and objectives of the new strategy adopted by the Board last November provide a strong institutional framework for the next five years.
In November, the Board decided to appoint a General Manager to oversee implementation of the Consolidated Transformation Plan who will report directly to the Board.  I respect this decision and trust that it was made in the best interests of the Global Fund.  I have reflected long and hard on the implications of this decision for me and for the organization.  While I remain fully committed to the Global Fund and its mission, I have concluded that I should not continue as Executive Director in these circumstances. 
I am committed to an orderly transition and I will do all that I can to ensure that the Global Fund emerges from it as a stronger organization.
I sincerely thank all members of the Global Fund staff for their commitment to the Global Fund.   Each and every person working in the Secretariat is making a direct and invaluable contribution to saving lives.   It has been a true privilege to work with such a committed, diverse and talented group of people.  There will be an informal event in March for us to say goodbye and for me to thank staff members personally for their efforts.
I thank everyone in the Fund’s major partner organizations for their support.  Without WHO, UNAIDS, UNDP, UNICEF, Stop TB, Roll Back Malaria, the Bill and Melinda Gates Foundation, Unitaid and the many civil society organizations that I have seen in action, Global Fund financing could not make such impact. 
I thank all the Friends organizations, particularly those in Europe, Japan, the US, Africa and the Pacific, whose advocacy and constant support for the Global Fund are so essential to its visibility and success.   I thank all the governments that are donors to the Global Fund.   And I thank our many other donors, including everyone associated with Product RED, as well as Bono, for their remarkable support.
Finally, I thank all the countries that are implementing AIDS, TB and malaria programs for their courage and commitment to fighting disease and improving the health of their people.  The opportunities that I have had to travel to many countries in the last five years and to see firsthand the difference that the Global Fund is making have been a tremendous source of personal inspiration.
As the Global Fund faces a challenging year of transition, it is more important than ever that staff, partners, donors, implementers, friends and supporters of the Fund pull together to maintain the remarkable hope that the Fund has generated around the world, and to keep up the fight.
With warm regards
Michel Kazatchkine


Letter from Laurie Garrett -- missing graphs.  Find original on her website.Laurie Garrett's website

The Global Fund: Can it be saved?
By Laurie Garrett, Senior Fellow for Global Health
January 24, 2012
Today Dr. Michel Kazatchkine tendered his resignation as Executive Director of The Global Fund to Fight AIDS, Tuberculosis, and Malaria (The Fund). Regardless of whether you’ve ever heard of the French AIDS scientist, or even of The Fund, you should keep reading. This is a critical, dangerous moment for all of Global Health.
In his letter delivered today to the Board of The Fund, Kazatchkine made clear the parameters of the political struggle that forced his resignation. “The Global Fund has helped to spearhead an entirely new framework of international development partnership. Although we still have a long way to go to make this new approach work in every country, I believe that the Global Fund has permanently changed the development landscape for the better,” Kazatchkine wrote.
But under stress during the world economic crisis, with radically declining support from donors, a battle has ensued, Kazatchkine wrote. “Today, the Global Fund stands at a cross-road. The prevailing economic climate poses new and formidable challenges to all international development efforts. In the international political economy, power-balances are shifting and new alignments of countries and decision-making institutions are emerging or will have to be developed to achieve global goals. Within the area of global health, the emergency approaches of the past decade are giving way to concerns about how to ensure long-term sustainability, while at the same time, efficiency is becoming a dominant measure of success.”
It is almost possible to hear Kazatchkine spitting out the words “efficiency” and “sustainability.” Indeed, a battle has been brewing since the financial crisis of November 2008 filtered pain down a year later on all types of foreign aid recipients, for everything from humanitarian crisis responses to malaria bed net distribution. Put in broad strokes, it is a fight between
Source Kaiser Family Foundation/ Jen Kates
those that believe the AIDS pandemic and allied diseases constitute global “emergencies” that must be tackled with full force, mistakes be damned; versus those that feel AIDS is now a chronic disease, managed with medication, requiring a permanent infrastructure of care and treatment that can eventually be operated and funded by the countries, themselves. It is a classic battle of titans, pitting urgency against long term sustainability.
The Fund was established ten years ago as a unique mechanism for moving billions of dollars from rich countries to poorer ones, to combat and treat three infectious diseases. Inspired by AIDS activists’ and physicians’ demands for access to life-sparing medicines, The Fund launched in 2002 in radical form. It is para-United Nations, meaning it is technically outside of the UN system, but all of the major health-related UN agencies and the World Bank sit on its Board. The Fund acts like a granting agency, accepting disease control and treatment application from governments and health organizations. The applications are reviewed by technical experts, often returned for redesign, and eventually deemed worthy of support. At the closure of a given grant cycle The Fund convenes a replenishment meeting, telling donors – mostly the governments of the U.S., U.K., France, and Germany – how much money is needed to support the accumulated grants.
This grant/replenishment mechanism is novel, unlike any other funding that directs resources for health or development from the North to the South, or from traditionally wealthy nations to the poorer ones. As designed, the mechanism puts recipients in the driver’s seat, stipulating how much money they want, and how they plan to spend it. Donors were assured that mechanisms were in place to monitor the cash flows, minimizing corruption, and maximizing the numbers of lives saved.
And The Fund worked. Just six years after its conception The Fund dispersed $2.3 billion in 2008. By 2010, The Fund was disbursing $3.5 billion annually. It was responsible for underwriting about 40 percent of all HIV treatment in poor countries and much of the care in middle-income nations such as China and India. More than two thirds of all malaria prevention and treatment in the world is now dependent on The Fund; three-quarters of all tuberculosis efforts. The Fund’s most marked impact has been on malaria, which has plummeted with infusion of cash for bed nets, insecticides, medicines and public health personnel. At the close of 2011 the World Health Organization (WHO) estimated that the number of malaria deaths fell 25 percent
between 2000 and 2010 – by a third in sub-Saharan Africa. In 2010, WHO reckons, 216 million people contracted malaria, which killed 655,000 of them.
A key point underscored repeatedly in a recently released WHO malaria report is that these successes reflect growing dependency on The Fund. The same is true for TB control. And while the United States government is by far the biggest supporter of HIV prevention and treatment programs, The Fund ranks second, and its collapse would leave more than a million HIV+ people without treatment, condemning them to swift death.
The prolonged recession and economic realignments are now hitting aid-dependent organizations hard, and will continue to exact budgetary pain for at least two more years. (If the Chinese financial wizards are right the world may be at the front end of a 25 year recession.) The initial reactions from global leaders like Kazatchkine was to scramble from donor to donor, hoping to garner guarantees of not only continued current-level financial support, but even expansion of funding to allow larger numbers of people to benefit from their services in poorer countries. Time was bought, and most of the major donors fulfilled their commitments in 2009 and 2010.
But with no end in sight to the economic downturn in the U.S., the tsunami-earthquake-Fukushima catastrophes in Japan and deepening crisis in the EuroZone, 2011 brought financial angst crashing down on Global Health. In October 2010 The Fund convened a replenishment meeting, asking donors for $20 billion for five years’ worth of disbursements. The donors were indignant: they committed just over half that amount. The Fund was flabbergasted.
After taking stock of its donor situation The Fund announced that it was cancelling the next grant round, and will not accept new grants until late 2013, disbursing those funds in 2014. Medecins Sans Frontiers and other health advocacy groups cried in protest, issuing estimates of numbers of people that would die for lack of new grants rounds.
The International Health Metrics and Evaluation Institute (IHME) in Seattle estimates that overall Global Health funding stagnated, and can only be expected to grow by 1-2 percent annually (if at all) over the next few years. Many programs are already feeling the budget blade in their backs. Humanitarian crises such as the famine in the Horn of Africa are groveling for handouts.
With this dire situation has come the search for more efficient ways to spend stagnating or shrinking resources: eliminate redundancies, better anticipate crippling foreign exchange rates amid monetary speculation, improve volume purchasing and supply chain management, and root out all semblances of corruption. Donor scrutiny increased. And under the bright lights of forensic financial investigation The Fund could not account for some $34 to $39 million. Moreover, specific “missing money” corruption cases opened in Mali, Mauritania, Djibouti, and Zambia, spawning loud protests from donors. Sweden, Germany and Ireland froze their monies for The Fund in escrowed accounts.
A High-Level Independent Review Panel convened in early 2011 to audit The Fund’s books, and investigate how the money was being spent at the country levels. In November the Panel released a condemning report, citing a litany of problems so lengthy that they cannot be summarized here: among them were fraud, theft, inconsistent decision-making by grant reviewers, nearly complete failure to develop metrics for reliably measuring the outcomes of The Fund’s spending, and sluggish disbursement from the organization’s Geneva headquarters.
The Board convened in Accra, Ghana on November 21, and by multiple accounts was stunned by the Panel report, and by internal audit findings. From a number of sources that attended the Accra meeting and subsequent Board gatherings I have gleaned a nightmarish picture. Some African leaders described riots and demonstrations protesting stock-outs of vital medicines, especially for HIV. Malaria experts said that even a momentary set-back in funding could swiftly push mosquito populations back to high levels, bringing the deadly parasites back to African and Asian villages.
The Board demanded Kazatchkine’s resignation. He refused.
The Board’s audit showed that The Fund has committed assets of $10 billion for 2011-13. But only about $4 billion was in its bank accounts. Auditors presented a “risk adjusted forecast for resources,” which demonstrated few avenues for fulfilling its commitments, much less taking on new ones.
The Board called for a Transitional Funding Mechanism, aimed at finding ways to stretch available resources, eliminate inefficiencies and get better bang for the HIV/malaria/TB buck. Key to that Mechanism would be appointment of a General Manager to oversee all spending, pushing Kazatchkine aside to a sort of figurehead status.
Kazatchkine refused. He was under tremendous pressure from the Sarkozy government – reportedly taking calls during the Accra meeting and following gatherings from the French Ministry of Foreign Affairs. It is an election year in France, and President Nicholas Sarkozy is battling a very cold image, seen by many of his voting population as an uncaring conservative that is putting Paris financial market concerns above the needs of the poor and middle class. He needs a softer asset – and The Fund has always been a darling of French foreign aid. February marks the 10th anniversary of The Fund, and Sarkozy plans a grand celebration in Paris, which must be chaired by the French head of The Fund.
The French situation was complicated further in 2011 when Kazatchkine was attacked in Paris newspapers for allegedly diverting Fund HIV money to a small foundation run by French First Lady Carla Bruni. A furious round of accusations and counter-accusations flew in the French media, but official investigations cleared Kazatchkine of all wrong-doing. He is not a member of Sarkozy’s party, nor a supporter of the President’s reelection. But Kazatchkine is French, and the prospect of a grand Parisian celebration of his institution’s 10th birthday was important.
Kazatchkine would not (could not) step down. And the Board’s selection for General Manager declined to step into the position so long as Kazatchkine remained.
Over the Christmas and New Years’ holidays, U.S. Secretary of State Hillary Clinton pressured the French, according to several sources that asked not to be identified, arguing that the very credibility of The Fund was on the line – Kazatchkine had to step down. She also gave a speech telling other donors to step up to the plate and support The Fund, noting that “to sit on the sidelines now would be devastating.”
Apparently a deal was finally struck, allowing Kazatchkine to stay in his position until March 16 (after the Paris celebration).
In his resignation letter today he writes, “As the Global Fund faces a challenging year of transition, it is more important than ever that staff, partners, donors, implementers, friends and supporters of the Fund pull together to maintain the remarkable hope that the Fund has generated around the world, and to keep up the fight.”
Stepping into the newly created position of General Manager of The Fund is Gabriel Jaramillo, who served on the High-Level Panel that audited The Fund in 2011. Columbia-born Jaramillio was CEO of Banco Santander Banespa Brasil, and previously was an executive for Citibank. Jaramillo served as Special Advisor to Malaria No More. At the World Economic Forum in Davos later this week Bill Gates will throw his support behind Jaramillo, pledging a 5-year funding commitment to The Fund that will significantly increase his foundation’s support above the current $100 million/year level. The government of Saudi Arabia announced this week that it will provide The Fund with $25 million in 2013. Similar proclamations are expected over coming days, following Kazatchkine's resignation letter, but it is unlikely the total in this flurry will top $500 million for 2013.
This tragic series of events has unfolded at The Fund amid a tremendous shake-up throughout Global Health. A similar set of events unfolded in 2010 at GAVI – the umbrella alliance for vaccines – nearly sinking the institution. But following a major overhaul of the institution, dismissal of its executive and intervention from Bill Gates, GAVI went into a funding meeting with donors in London in June. It came out with more than a billion dollars than it requested, thanks largely to U.K. Prime Minister David Cameron, and has a popular new leader, Dr. Seth Berkley (founder of the International AIDS Vaccine Initiative).
WHO is also in the middle of a major shake-up that has in recent months featured lay-offs of 300 employees and a $1 billion budget cut. Director-General Margaret Chan is executing a top-to-bottom reform of the agency that is both painful and necessary.
We can hope that this awful moment in The Fund’s history will leave the institution stronger, tougher, and better supported in 2013.
From Kaiser Family Foundation/ Jen Kates



Saturday, 3 December 2011

Global Fund cancels next round of grants..

http://www.guardian.co.uk/society/sarah-boseley-global-health/2011/nov/23/aids-tuberculosis

http://www.ft.com/cms/s/0/b7392674-1a7c-11e1-ae4e-00144feabdc0.html#axzz1fSesKEKN

November 30, 2011 4:42 pm

Global Fund: reform needed to regain credibility

The Global Fund to Fight Aids, Tuberculosis and Malaria, one of the major funders for HIV/Aids programmes around the world, is facing an unprecedented moment of crisis as it announced last week that it has run out of funding to pay for new grant programmes for the next two years.
Tight economic conditions and recent reports of fraud, theft and corruption among its grantees set the stage for this dramatic decision by its board on November 23 – a decision that is likely to impact poor Aids patients around the world. Recovering from this setback and continuing to pursue its ambitious mission will require bold action by the Fund and significant shifts in what it requires from grant recipients, how it tracks progress and how it ensures accountability for results.

A decade after its founding, the Fund is the largest financier in the fight against these three killer epidemics and has not only saved millions of lives directly through its grants but has shifted market dynamics for antiretroviral medications (ARVs) in ways that make treatment more affordable in the long run. As it now seeks to right its course, it has already taken important steps to chart a new course with an emphasis on accountability, efficiency and additionality – i.e., ensuring that its funding doesn’t displace existing financial resources.
Earlier in October a high-level independent review panel on fiduciary controls and oversight mechanism (HLP) had recommended major changes to the accountability structures at the Fund. The panel’s recommendations, most of which have been adopted by the Fund, were centred on shifting it to focus on outcomes instead of inputs, instituting tiers of grant requirements, and creating better accountability structures within the Fund by repurposing committees, empowering middle managers, and adding positions with an explicit focus on risk management. These recommendations are likely only to create a slow, costly and rigid bureaucracy that delivers only marginal benefits to accountability and effectiveness.
The challenges faced by the Fund today present an important window of opportunity for it to drive reform while preserving its lean design principles that will make it not only more transparent and accountable, but also more agile, responsive and efficient. This can be achieved by driving data-based accountability from the bottom-up, empowering the Fund’s ultimate recipients and partners to provide real time feedback on the performance of the programmes it supports.
One of the most obvious places to achieve this change is in the supply chains its recipients use for delivering medicines and other health products. Through better information collection, particularly using mobile telephony, and enabling a multiplicity of players to participate in those supply chains, efficiency and transparency could be radically improved.
The inclusion of recipient feedback could be part of a lean multi-channel platform which would allow the Fund to make better use of information, create greater transparency, and have more effective tools to manage performance. Previously, incorporating feedback from end-recipients, village councils, professional bodies, fragmented civil society organisations and so forth was prohibitively expensive. But with the spread of mobile and broadband networks within developing countries there is now an unprecedented opportunity to improve the transparency, tracking and evaluation of the Fund’s programmes by collecting data and opening channels of communication between it, its suppliers, the end-users of its products and services, and the intermediaries.
Creating this multi-platform system would require the Fund to rethink its overall accountability architecture, creating new channels for communication not only with end recipients, but also with actors and stakeholders throughout supply and distribution chains.
There are several examples which demonstrate the potential of this bottom-up accountability. For example, years of investment and top-down planning and accountability structures have not been able to address stock-outs at the health facility level. A new programme, SMS for Life, has cut stock-outs of malaria medicines in regions of Tanzania to extremely low levels by linking health facilities to district medical offices through mobile phone-based communication. Using the data collected from health facilities and internet mapping software, the district offices have been able to redistribute stock in the most efficient way possible, saving time and transport costs.
Similarly, the Stop Stock-Outs Campaign, which covered four countries in southern and eastern Africa, used a combination of Ushahidi crowdsourcing software and the FrontlineSMS communication platform to collect reports of stock-outs of essential medicines for six months in 2009 and 2010. It received hundreds of reports, providing a template for consumer monitoring of health services. Admittedly, these examples may not be usable in their current form and structure for the scale required by the Fund. However, they do demonstrate that citizens and end-beneficiaries can be fertile sources of rich and highly granular information about medicine availability and that efficient mechanisms can be created for incorporating end-beneficiary feedback to drive bottom-up accountability.
Similarly, drug regulation is another area that is traditionally governed by top down accountability with national drug regulatory authorities having the responsibility of ensuring safety, efficacy and quality of medicines. The birth of applications such as Sproxil, Pharmasecure, and mPedigree, which allow consumers and pharmacists to send codes marked on products to central databases via text messages to check the products’ authenticity, demonstrates the power of bottom-up accountability in combating counterfeits. They also show how bottom-up mechanisms can work in concert with top-down accountability structures, linking consumer actions and input to governance and oversight bodies. The same kind of communication would allow the Fund to verify the delivery of commodities purchased by grantees.
These kinds of bottom-up accountability mechanisms will need to be institutionalised – covering all suppliers and grantees – if they are to realise their potential. In the private sector, large corporations with the most sophisticated monitoring and control systems that measure multiple metrics at all levels in a system, invest heavily in tools which allow them to tap into the voice of the customer, as this creates a direct link for feedback. This process need not be burdensome, though; the appropriate system would be one that is focused on lean structures, savvy uses of technology, and has a relentless focus on incorporating the voice of recipients – the Fund’s “customers” – to drive accountability and to improve overall performance.
Similarly, there will need to be a move away from exclusively government-run medicine distribution systems. Inefficiency and corruption is inevitable in a system where the government has near monopoly over delivery of drugs and health services, government employees who run the programmes are lowly and irregularly paid, and there is lack of granular data to hold anyone accountable. Transport, warehousing and distribution of drugs, and the data systems that enable supply chains to operate efficiently, are not core strengths of any government. Even the most publicly funded health systems in OECD countries use private sector entities to manage their supply chains.
To ensure that products procured from the Fund’s grants reach the end-beneficiaries effectively and efficiently, the locus of accountability has to become more dispersed; it has to shift from government offices alone to end-beneficiaries and private sector entities. Creating accountability “pressure points” outside the government and removing the government’s monopoly on distribution to the extent possible, will be vital in making delivery systems more responsive, efficient and accountable.
New accountability mechanisms will require new sanctions, too, otherwise they will be short-lived. Bottom-up accountability without top down enforcement is futile. The availability of data collected from bottom-up mechanisms, especially, will increase the accessibility of performance metrics and may strengthen the feasibility of bold performance-based funding. Equally important, it will allow the Fund to focus more on the needs of its intended beneficiaries, with whom it has had limited direct communication to date.
The Fund was formed with the recognition that the old ways of development aid – top-down, tightly controlled efforts, steeped in bureaucratic controls and dependent on large numbers of international staff – didn’t work, and too often built programmes that were poorly matched to local needs, lacked local leadership and were ultimately unsustainable. The Fund risks going down that path in the name of accountability. With more timely, robust and better-utilised bottom-up information on its supply chain and ultimate recipients, it doesn’t have to.
Vicky Hausman is an associate partner at Dalberg Global Development Advisors in New York and leads the firm’s global health practice.
Prashant Yadav is the director of healthcare research at the William Davidson Institute at the University of Michigan (Corresponding author).
Daniella Ballou-Aares is a partner at Dalberg Global Development Advisors in New York and is director of its North American Business.
Brad Herbert is an independent consultant and was formerly the chief of operations at the Global Fund to Fight Aids, TB and Malaria.